Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
21.72
+0.04 (0.18%)
Sep 29, 2026, 10:10 AM EDT - Market open
Immunome Revenue
In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
247
Market Cap
2.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Nurix Therapeutics | 36.77M |
| Celldex Therapeutics | 158.00K |
IMNM News
- 8 days ago - Immunome initiated with a Buy at Alliance Global - TheFly
- 14 days ago - Immunome Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 20 days ago - Immunome Slides: Corporate presentation - Filings
- 20 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
- 6 weeks ago - Immunome price target raised to $35 from $31 at Wedbush - TheFly
- 6 weeks ago - Immunome reports Q2 EPS (65c), consensus (50c) - TheFly
- 6 weeks ago - Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire